Source:http://linkedlifedata.com/resource/pubmed/id/18563007
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2008-6-19
|
| pubmed:abstractText |
Fabry disease is an inherited, progressive, life-threatening disease; therefore, lifelong therapy is needed. By replacing the deficient enzyme, disease progression may be delayed or halted, thereby avoiding serious complications. Hospital-based agalsidase therapy is generally perceived as inconvenient and home-based infusion therapy is greatly appreciated by patients, their families and healthcare professionals. Patients can get familiar with infusion therapy in a hospital setting and, if specific requirements are fulfilled, routine nurse-assisted infusion, or self-care, at the patient's home can be organized. A stable patient who tolerates the infusion and a suitable home environment are prerequisites for home therapy. The authors' clinical experiences underscore the safety and practicality of home therapy. In addition to a major positive impact on the patient's quality of life, home infusion therapy may reduce the constraints of hospital resources. This article reviews the collective experiences with agalsidase beta home infusion therapy and outlines how safe, patient-centred homecare can be organized. Home infusion therapy with Fabrazyme should not be withheld from patients considered eligible according to the proposed criteria. Similar approaches to other enzyme therapies are also possible.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
N
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0966-0461
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
653-7
|
| pubmed:meshHeading |
pubmed-meshheading:18563007-Community Health Nursing,
pubmed-meshheading:18563007-Disease Progression,
pubmed-meshheading:18563007-Drug Monitoring,
pubmed-meshheading:18563007-Fabry Disease,
pubmed-meshheading:18563007-Great Britain,
pubmed-meshheading:18563007-Home Care Services,
pubmed-meshheading:18563007-Home Infusion Therapy,
pubmed-meshheading:18563007-Humans,
pubmed-meshheading:18563007-Isoenzymes,
pubmed-meshheading:18563007-Israel,
pubmed-meshheading:18563007-Netherlands,
pubmed-meshheading:18563007-Nurse's Role,
pubmed-meshheading:18563007-Nursing Assessment,
pubmed-meshheading:18563007-Patient Compliance,
pubmed-meshheading:18563007-Patient-Centered Care,
pubmed-meshheading:18563007-Practice Guidelines as Topic,
pubmed-meshheading:18563007-Quality of Life,
pubmed-meshheading:18563007-Safety Management,
pubmed-meshheading:18563007-United States,
pubmed-meshheading:18563007-alpha-Galactosidase
|
| pubmed:articleTitle |
Home-based infusion therapy for patients with Fabry disease.
|
| pubmed:affiliation |
Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK.
|
| pubmed:publicationType |
Journal Article,
Review
|